Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LUCD
Upturn stock ratingUpturn stock rating

Lucid Diagnostics Inc (LUCD)

Upturn stock ratingUpturn stock rating
$0.98
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: LUCD (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $3.62

1 Year Target Price $3.62

Analysts Price Target For last 52 week
$3.62 Target price
52w Low $0.73
Current$0.98
52w High $1.8

Analysis of Past Performance

Type Stock
Historic Profit -33.02%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 106.15M USD
Price to earnings Ratio -
1Y Target Price 3.62
Price to earnings Ratio -
1Y Target Price 3.62
Volume (30-day avg) 6
Beta 1.21
52 Weeks Range 0.73 - 1.80
Updated Date 08/15/2025
52 Weeks Range 0.73 - 1.80
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.95

Earnings Date

Report Date 2025-08-13
When -
Estimate -0.11
Actual -0.1

Profitability

Profit Margin -
Operating Margin (TTM) -978.85%

Management Effectiveness

Return on Assets (TTM) -82.33%
Return on Equity (TTM) -463.56%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 156998728
Price to Sales(TTM) 24.35
Enterprise Value 156998728
Price to Sales(TTM) 24.35
Enterprise Value to Revenue 36.01
Enterprise Value to EBITDA -0.67
Shares Outstanding 108195000
Shares Floating 66851146
Shares Outstanding 108195000
Shares Floating 66851146
Percent Insiders 34.45
Percent Institutions 18.62

ai summary icon Upturn AI SWOT

Lucid Diagnostics Inc

stock logo

Company Overview

overview logo History and Background

Lucid Diagnostics Inc. was founded in 2018. It focuses on developing and commercializing tools for early detection of esophageal cancer, specifically in patients with Barrett's esophagus.

business area logo Core Business Areas

  • EsoGuardu00ae Esophageal DNA Test: Non-endoscopic diagnostic test to detect esophageal precancer and cancer in patients with Barrett's esophagus.
  • EsoChecku00ae Esophageal Cell Collection Device: Device used to collect esophageal cells for subsequent analysis by the EsoGuard test.

leadership logo Leadership and Structure

The company is led by a management team focused on commercialization and clinical development, structured with a board of directors and executive leadership.

Top Products and Market Share

overview logo Key Offerings

  • EsoGuardu00ae Esophageal DNA Test: A laboratory-developed test (LDT) used to detect biomarkers associated with Barrett's esophagus and esophageal adenocarcinoma. Market share data is difficult to determine due to the limited adoption and fragmented nature of the market for early cancer detection tools. The competitors are mainly endoscopic surveillance procedures, and novel technologies from companies like Medtronic. Revenue information is not easily available due to the company's developmental stage.
  • EsoChecku00ae Esophageal Cell Collection Device: A swallowable device used to collect cells for EsoGuard. This is used in combination with EsoGuard, making it a companion product. Market share data for collection devices specifically is not publicly available. Competitors in this market are traditional endoscopic methods and other cell sampling techniques.

Market Dynamics

industry overview logo Industry Overview

The industry involves early cancer detection, with a focus on non-invasive diagnostic methods. The sector is characterized by increasing demand for less invasive and more cost-effective diagnostic tools.

Positioning

Lucid Diagnostics is positioned as an innovator in non-endoscopic esophageal cancer detection. Its competitive advantage lies in the ease of use and patient comfort associated with its EsoCheck/EsoGuard system.

Total Addressable Market (TAM)

The TAM for esophageal cancer detection is estimated to be in the billions of dollars, considering the high prevalence of Barrett's esophagus. Lucid is positioned to capture a portion of this TAM through its novel, non-invasive approach. A definitive number is difficult to assess due to changing market conditions and adoption rates.

Upturn SWOT Analysis

Strengths

  • Non-invasive technology
  • Ease of use for both patients and physicians
  • Potential for early cancer detection
  • Proprietary EsoGuard test

Weaknesses

  • Limited clinical adoption
  • Dependence on third-party payers for reimbursement
  • High cost of goods sold
  • Needs more robust clinical data.

Opportunities

  • Expansion of EsoGuard testing into primary care settings
  • Increasing awareness of Barrett's esophagus
  • Development of new biomarkers for cancer detection
  • Partnerships with gastroenterology practices and hospitals.

Threats

  • Competition from established endoscopic procedures
  • Regulatory hurdles for new diagnostic tests
  • Lack of insurance coverage for EsoGuard testing
  • Slower than expected adoption by physicians

Competitors and Market Share

competitor logo Key Competitors

  • MDGL
  • BSX
  • JNJ

Competitive Landscape

Lucid Diagnostics offers a unique non-invasive solution, but faces competition from established endoscopic methods and larger medical device companies like Medtronic. Lucidu2019s advantage is its patient friendly approach but suffers from limited clinical data and adoption.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been slow, with gradual increases in revenue as the company works to drive adoption of its EsoGuard test.

Future Projections: Future growth is dependent on successful commercialization, expansion of insurance coverage, and clinical validation. Analyst estimates are speculative and depend on the company's ability to execute its business plan.

Recent Initiatives: Recent initiatives include expansion of the sales force, partnerships with gastroenterology practices, and efforts to secure reimbursement from third-party payers.

Summary

Lucid Diagnostics is an early-stage company with a novel non-invasive cancer detection technology. It faces significant challenges in driving adoption, securing reimbursement, and competing with established medical procedures. The company needs to generate more revenue and further validate its technology with additional clinical data. Success depends on the execution of its commercialization strategy and overcoming regulatory and payer hurdles.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Presentations
  • Analyst Reports
  • Industry News and Publications

Disclaimers:

This analysis is based on publicly available information and should not be construed as investment advice. Financial data is subject to change and may not be perfectly accurate. Market share data is based on estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lucid Diagnostics Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2021-10-14
Chairman & CEO Dr. Lishan Aklog M.D.
Sector Healthcare
Industry Medical Devices
Full time employees 72
Full time employees 72

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.